Listing analysis and research matching Cancer:
Tykerb's implications for partnerships
On March 13 2007 GlaxoSmithKline's cancer drug Tykerb (lapatinib ditosylate) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer. Targeted to patients who carry the HER2 gene, the approval opens up partnership opportunities in the field of diagnosis and pharmacogenomics.
Hollis-Eden Pharmaceuticals cuts staff by 25%
San Diego-based Hollis-Eden Pharmaceuticals Inc has announced that it will cut 25% of its staff.
GE and Lilly ink cancer diagnostics linkup
In a sign of the accelerating convergence between treatments and diagnostics GE and Eli Lilly have announced a collaboration to develop in vitro diagnostic assays that may help predict cancer treatment response to targeted therapies.
Public-private partnerships for drug development: An emerging trend or special cases?
On November 5th 2007 the pharmaceutical company GlaxoSmithKline announced that it had formed a five year alliance with the Texan based non-profit research institution MD Anderson Cancer Center to discover and develop new therapeutic, diagnostic and imaging products for cancer.
